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1718Genetic Variations of Interleukin-23R (1143A.G)
and BPI (A645G), but Not of NOD2, Are Associated
with Acute Graft-versus-Host Disease after
Allogeneic Transplantation
Martin Wermke,1 Stefanie Maiwald,2 Renate Schmelz,1 Christian Thiede,1
Johannes Schetelig,1 Gerhard Ehninger,1 Martin Bornha¨user,1 Ralf Wassmuth2Single nucleotide polymorphisms (SNPs) in genes of the immune system predict for aGVHD and mortality
after allo-SCT. We investigated the effect of SNPs in the NOD2, BPI, and IL-23R genes on posttransplantation
outcome in a cohort of 304 patients.NOD2 patient and donor genotype and BPI recipient genotype were not
associated with the occurrence of aGVHD. However, IL-23R-SNP in the donor was correlated with less
aGVHD. This association could be confirmed in multivariate analysis (odds ratio [OR], 0.39; P5.039), which
identified in vivo T cell depletion (OR, 0.32; P\.001) and multiagent GVHD prophylaxis (OR, 0.51; P5.031)
as other independent factors predicting for less-severe aGVHD. This multivariate model also revealed a trend
toward less aGVHD in patients receiving a BPI G allele transplant (OR, 0.60; P5 .067) and in those receiving
a transplant from an HLA-matched donor (OR, 0.57; P 5 .058). In contrast, relapse was more frequent in
patients with NOD2-SNPs (46.2% for SNP vs 33.2% for wild-type; P 5 .020). This association was found
to be of borderline significance in multivariate analysis. Neither BPI nor IL-23R genotype predicted for re-
lapse, and none of the investigated SNPs was correlated with 5-year overall survival. In our analysis,
NOD2 SNPs did not predict aGVHD, but IL-23R(1142A.G) and BPI(A645G) SNPs appeared to be promising
markers in this regard. The importance of these markers in prediction models for GVHD and relapse remain
to be defined in large prospective clinical trials.
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Allogeneic stem cell transplantation (allo-SCT)
represents the only treatment offering cure, or at least
long-term progression-free survival, for many leuke-
mia and lymphoma patients. Despite recent advances,
however, treatment-related mortality (TRM) remains
at disappointingly high levels, with acute and chronic1University Hospital Carl-Gustav-Carus, Department of
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6/j.bbmt.2010.06.001graft-versus-host disease (GVHD) being one of the
main causes of treatment failure. Efforts to separate
these potentially lethal complications from beneficial
graft-versus-tumor effects have not been widely suc-
cessful so far. Thus, scientific interest has shifted
somewhat from improving HLA matching to under-
standing the contribution of minor histocompatibility
antigens and the innate immune system (reviewed by
Penack et al. [1]). A milestone in the latter area was
the identification of single nucleotide polymorphisms
(SNPs) in the NOD2/CARD15 gene as predictors for
the occurrence of acute GVHD (aGVHD) by Holler
et al. [2] in 2004. The NOD2 protein functions as an
intracellular sensor for the bacterial cell wall product
muramyl-dipeptide and is believed to play an impor-
tant role in maintaining the integrity of the mucosal
barrier [3]. DefectiveNOD2 functionmight lead to in-
efficient clearance of bacterial pathogens, resulting in
subsequent hyperinflammation, which in turn pro-
motes the development of aGVHD. The results of
retrospective analyses are somewhat contradictory,
Biol Blood Marrow Transplant 16:1718-1727, 2010 1719SNPs and aGVHDhowever, with some studies supporting NOD2-SNPs
as a significant factor for aGVHD [2,4,5] but others
not demonstrating such effects [6,7]. The importance
of NOD2 mutations seems to depend on the clinical
context [8,9]; clearly, NOD2-SNPs alone are insuffi-
cient to adequately predict the risk for aGVHD in
the general population of patients undergoing allo-
SCT.
Another candidate gene that possibly affects the
risk of immunologic complications after allo-SCT is
the bactericidal permeability-increasing protein
(BPI). BPI is a 55-kDa antimicrobial polypeptide that
is preferentially expressed in neutrophils and to a lesser
extent in mucosal epithelial cells [10]. It exerts direct
antimicrobial effects, neutralizes lipopolysaccharides
(LPS), and opsonates gram-negative bacteria [11].
Like NOD2, BPI is believed to be an essential part
of the complex system that maintains mucosal integrity
against a wide variety of commensal and pathogenic
microbes. Recently, an SNP at position 645 of the
BPI gene (A vs G) was associated with Crohn’s disease
[12]. BPI-SNPs also have been found to affect the risk
of bronchiolitis obliterans syndrome (BOS) after allo-
SCT [13]. The potential effect of BPI-SNPs on the de-
velopment of aGVHD has not yet been studied.
Our understanding of autoimmune and inflamma-
tory processes was recently broadened significantly by
the identification of a novel subset of T helper cells,
designated Th17 cells. These Th17 cells are character-
ized by the expression of interleukin (IL)-17 and IL-22
and induce IL-1b, IL-6, tumor necrosis factor a,
granulocyte macrophage colony-stimulating factor,
granulocyte colony-stimulating factor, and several
chemokines, thereby promoting local accumulation
of inflammatory cells and a systemic inflammatory
reaction. This seems to apply to aGVHD as well, given
the report that lethal GVHD could be induced by in
vitro-differentiated Th17 cells in mice [14]. IL-23 is
an essential cytokine for the maintenance and prolifer-
ation of these cells, and, accordingly, lack of IL-23 led
to less aGVHD in a murine transplantation model
[15]. On the other hand, Das et al. [16] reported that
IL-23 knockout protects against GVHD independent
of Th17 cells in a Balb/c-B6 mouse model. Data in
humans further corroborate the association of the
IL-23 pathway with GVHD by demonstrating that
individuals bearing an SNP in the IL-23 receptor
(IL-23R) gene are less likely to experience aGVHD
after allo-SCT [17].
In the present study, we investigated the role of
SNPs in the genes coding for NOD2, BPI, and IL-
23R as predictors for the occurrence of aGVHD after
allo-SCT. We chose these loci because all have been
associated with the occurrence of inflammatory bowel
disease, which in many ways serves as a model for the
propagation of aGVHD at the host-microbial inter-
face. Because GVHD often correlates with graft-versus-malignancy effects as well as with TRM, we
also investigated the role of these genetic variants in
relapse and overall survival (OS). We retrospectively
screened for SNPs in these 3 genes in a cohort of
304 patients and their respective donors.PATIENTS AND METHODS
Patients and Donors
All patients who underwent transplantation at our
center, between November 2001 and January 2006,
were eligible for this retrospective analysis. Of a total
of 455 patients, 108 had to be excluded because of in-
sufficient patient and/or donor material. Furthermore,
to homogenize our study cohort, 43 individuals were
excluded because of incomplete clinical data, haploi-
dentical transplantation, ex vivo T cell-depletion strat-
egies, or nonstandard indications for transplantation
(eg, metabolic diseases, solid tumors). There were no
relevant demographic differences between included
and excluded patients, and both cohorts consisted
only of individuals of central European, Caucasian
origin. Further details about the excluded patients
are provided as supplementary material (Table S1).
In total, the study cohort comprised 304 patients
who underwent allo-SCT from an HLA-matched
related donor or from an at least 8/10 HLA-matched
unrelated donor. In patients receiving a graft from
a matched related donor, HLA matching was based
on low-resolution (2-digit) typing for HLA-A, -B, and
-C and on high-resolution typing (4-digit) for HLA-
DRB1 and -DQB1. Typing in the matched unrelated
setting was done in the sameway until 2003, after which
HLA class 1 molecules were also subjected to high-
resolution typing. Details on patient and treatment
characteristics are presented in Table 1. All patients
received antimicrobial prophylaxis with 500 mg of
ciprofloxacin per day. For myeloablative conditioning,
oral metronidazole 250 mg 3 times daily was added,
and patients were treated under reverse isolation from
the beginning of chemotherapy. Reduced-intensity
conditioning (RIC) was based mainly on fludarabine
plus total body irradiation (TBI), busulfan, or melpha-
lan and thus can be characterized as myeloablative.
For standard-intensity conditioning, cyclophosphamide
(120mg/kg) in combination with either 12Gy of hyper-
fractionated TBI or busulfan and etoposide plus 12 Gy
TBI were the most frequently used regimens. Antithy-
mocyte globulin (ATG Fresenius) was used for in
vivo T cell depletion in most patients who received
a transplant from a matched unrelated donor. GVHD
prophylaxis was provided by a calcineurin inhibitor
(cyclosporine A or tacrolimus) either alone or in combi-
nation with methotrexate or mycophenolate mofetil.
GVHD grading was based on clinical criteria and/or
histological analysis according to standard criteria [18].
Table 1. Characteristics of the 304 Patients Enrolled
Age, years, median (range) 50.8 (11-76)
Sex, n (%)
Female 126 (41.4%)
Male 178 (58.6%)
Diagnosis, n (%)
AML/MDS 158 (52.0%)
Lymphoma 77 (25.3%)
Myeloma 22 (7.2%)
ALL 25 (8.2%)
Myeloproliferative syndrome 17 (5.6%)
Other 5 (1.6%)
Status at transplantation, n (%)
Compete remission, CML in
chronic phase, MDS
139 (45.7%)
Advanced 165 (54.3%)
Conditioning, n (%)
Standard 70 (23.0%)
RIC 234 (77.0%)
In vivo T cell depletion, n (%)
Yes 96 (31.6%)
No 208 (68.4%)
Donor, n (%)
Related 100 (32.9%)
Unrelated 204 (67.1%)
HLA match, n (%)
Match (10/10) 231 (76.0%)
Mismatch (9/10 or 8/10) 73 (24.0%)
Donor sex, n (%)
Female donor/male recipient 45 (14.8%)
Other 259 (85.2%)
Transplant source, n (%)
PBSC 288 (94.7%)
BM 16 (5.3%)
1720 Biol Blood Marrow Transplant 16:1718-1727, 2010M. Wermke et al.All patients provided informed consent during the
hospital stay. The banking of DNA for genetic studies
and their correlation with clinical endpoints was
approved by the local Institutional Review Board.SNP Nomenclature
Given that published data suggest a dominant effect
of NOD2- and IL-23R-SNPs on posttransplantation
outcome, we focused our analysis on the dominant ge-
netic model. Furthermore, given the low minor allele
frequencies of both SNP, it would have been necessary
to include far more patients than available at a single
center to design an adequately powered study address-
ing additive or even recessive models. A dominant
genetic model means that all patients and donors carry-
ing at least one mutated allele in NOD2 exon 8
(rs2066844), 12 (rs2066845), or 13 (rs2066847) were
classified as NOD2-SNP. Individuals bearing only the
wild-type (wt) allele at each locus were classified as
NOD2-wt. Likewise, all individuals bearing at least
one variant allele at position 1142 of the IL-23R gene
(rs11209026) were classified as IL-23R-SNP, whereas
those with only the wt allele were classified as IL-
23R-wt. In terms of BPI, the presence of at least one
G allele at position 645 (rs4358188) was required for
classification as BPI-G. Individuals with two A alleles
were classified as BPI-A under this model. Given thepublished frequencies of the A and G alleles, we evalu-
ated additive and recessive models for BPI as well.
DNA Analysis
DNA analysis was done without knowledge of
GVHD or clinical outcome status. DNAwas extracted
from blood or bone marrow (BM) obtained from
donors and recipients before transplantation using
a silica-based procedure (Qiagen DNA Blood Kit;
Qiagen, Hilden, Germany) and frozen until analysis.
Whole genome amplification was performed using
the GenomiPhi V2 DNA amplification kit (GE
Healthcare, Munich, Germany) according to the
manufacturer’s recommendations.
Real-time polymerase chain reaction (PCR) geno-
typing for NOD2-SNP8, -SNP12, and -SNP13, IL-
23R-SNP, and BPI-SNP was done with a Lightcycler
480 (Roche, Mannheim, Germany). Primers, probes,
and Taqman Universal PCR master mix were pur-
chased fromApplied Biosystems (AppleraDeutschland,
Darmstadt, Germany). Probes were labeled with either
FAM or VIC and a nonfluorescent quencher. The final
25-mL reaction mix contained 12.5 mL of Taqman
Universal PCR master mix (Applied Biosystems,
Applera Deutschland), 1.25 mL of the predesigned or
custom-made SNP assay, and 10 ng ofDNA. PCR con-
ditions were 10 seconds at 95C, followed by 40 cycles
of 15 seconds at 92C and 1 minute at the annealing/
extension temperature (60C for NOD2-SNP12,
NOD2-SNP13, and BPI and 62C for NOD2-SNP8
and IL-23R-SNP). For quality control, specimens
with a known genotype at each analyzed locus and
no-template controls were included in every run of
whole genome amplification and real-time PCR.
Statistical Analysis
Because of the low expected frequencies of the
variant allele, the exact test as described byWigginton
et al. [19] was used to assess Hardy-Weinberg equilib-
rium. For time-dependent variables, patients were
censored at the time of last follow-up. aGVHDwas de-
fined as any GVHD occurring before day 100. Day
1100 incidences are reported. The cumulative inci-
dence of aGVHD was analyzed by competing-risk
analysis using Gray’s test for comparison of groups.
For that purpose, GVHD was classified as either clin-
ically relevant (grade II-IV) or severe (grade III-IV)
and compared with no or uncertain GVHD (grade
0-I) and no or nonsevere GVHD (grade 0-II), respec-
tively. Death without GVHDwas treated as a compet-
ing event. Multivariate analysis of the aGVHD rates
was performed using an ordinal logit regression model
to account for the varying clinical and prognostic
implications of the different aGVHDgrades. The pro-
portionality assumption was checked by allowing the
coefficients of the independent variables to vary for
Biol Blood Marrow Transplant 16:1718-1727, 2010 1721SNPs and aGVHDdifferent logits, and then testing for differences among
these coefficients. Advanced disease was defined as
a disease not in complete remission or not having
chronic myelogenous leukemia in chronic phase or
myelodysplastic syndrome (MDS). Relapse incidence
was estimated using competing events statistics as de-
scribed before, with death as a competing event. Cox
regression was applied to search for biologic factors as-
sociated with the risk of relapse. OS was assessed using
the Kaplan-Meier method, with death from any cause
as the endpoint. The log-rank test was used for com-
parisons among the different groups. Statistical analy-
ses were performed with R version 2.8.1 with the
cmprsk package (Cran network) and SPSS version
17.0 (SPSS, Munich, Germany).RESULTS
In our somewhat older study cohort (median
age, 51 years), RIC was used in two-thirds of cases
(Table 1). Most patients received peripheral blood
stem cells (PBSCs) (94.7%) from a matched unrelated
donor (67.1%). The median follow-up time for living
patients was 38.5 months (range, 0.7-75.5 months).Frequencies of Individual SNPs
Minor allele frequencies forNOD2-SNP8, - SNP12,
and -SNP13 and IL-23R as well as BPI SNP645 G allele
frequency were similar to those published by the NCBI
SNP project (http://www.ncbi.nlm.nih.gov/projects/
SNP). Details can be found in IL-23R Tables 2 and 3.
Only 4 patients were homozygous for NOD2-
SNP8. All other patients and donors displayed either
homozygous wt or heterozygous variant genotype at
the NOD2-SNP8, -SNP12, or -SNP13 loci. Only
1 patient and 5 donors had mutations at more than
1 of the 3NOD2-SNP loci and thus could be classified
as compound heterozygotes. Homozygous IL-23R
mutations were found in only 2 of 304 recipients and
in only 2 of 304 donors. In contrast, 92 of 304 recipi-
ents (30.3%) and 81 of 304 donors (26.6%) demon-
strated homozygosity for the G allele at position 645
of the BPI gene. Tables 2 and 3 list the numbers of
patients with the homozygous wt, heterozygous SNP,
and homozygous SNP genotypes.Table 2. Genotype and Allele Frequencies of the Analyzed Loci in
Wt/Wt, n (%) Wt/Variant, n (%)
NOD2 SNP8 278 (91.4%) 22 (7.2%)
NOD2 SNP12 290 (95.4%) 14 (4.6%)
NOD2 SNP13 283 (93.1%) 21 (6.9%)
BPI 71 (23.4%) 141 (46.4%)
IL-23R 256 (84.2%) 46 (15.1%)
f(wt or variant) indicates wt or variant allele frequency; BPI, bactericidal permWhen assessing whether the observed frequencies
are reconcilablewith theHardy-Weinberg equilibrium,
wenoticed that thiswas not the case forNOD2-SNP8 in
the recipients (P5 .007; Table 2). This is because of an
excess of patients bearing the homozygous SNP geno-
type (n5 4). In contrast, recipient genotype frequencies
for NOD2-SNP12 (P5 1.0), NOD2-SNP13 (P5 1.0),
BPI (P 5 .272), and IL-23R (P 5 1.0) were consistent
with the Hardy-Weinberg equilibrium. The same
applied for donor genotypes frequencies for NOD2-
SNP8 (P 5 .846), NOD2-SNP12 (P 5 1.0), NOD2-
SNP13 (P5 1.0), BPI (P5 1.0), and IL-23R (P5 .511).
Polymorphisms and GVHD
Overall, 110 of 304 patients (36.2%) experienced
aGVHD grade II-IV with a median time to onset of
19 days (range, 6-93 days). Severe aGVHD (grade
III-IV) occurred in 52 of 304 patients (17.1%) at
a median of 21 days (range, 6-88 days) after allo-
SCT. Gastrointestinal (GI) GVHD of any grade was
diagnosed in 64 of 304 patients (21.1%) at a median
of 20 days (range, 6-88 days) after allo-SCT.
NOD2 polymorphisms
The cumulative incidence of clinically relevant
aGVHD (grade II-IV) was not significantly different
between patients who received transplants from
NOD2-wt and NOD2-SNP donors (Figure 1A) at
day 100 after transplantation (37.3%; 95% CI,
31.18%-43.5% vs 32.6%; 95% CI, 21.3%-43.9%;
P 5 .623). Similarly, NOD2 recipient genotype was
not found to correlate with the incidence of aGVHD
grade II-IV (Figure 1B). The cumulative incidence
was 37.0% in patients with wt (95% CI, 30.9%-
43.1%) and 33.3% in those with variant NOD2 geno-
type (95% CI, 21.3%-45.4%; P 5 .601). To further
dissect the influence of NOD2-SNPs on the occur-
rence of aGVHD, we divided patients into 4 sub-
groups according to the NOD2 genotype of the
recipient and the donor (group 1: recipient and donor
wt; group 2: recipient SNP and donor wt; group 3:
recipient wt and donor SNP; group 4: recipient and
donor SNP). As shown in Figure 1C, the cumulative
incidence function did not differ significantly among
the 4 subgroups.
Donor NOD2 genotype did not influence the
occurrence of severe aGVHD (donor NOD2-wt:the Recipients
Variant/Variant, n (%) f(wt) f(variant)
4 (1.4%) 0.95 0.05
0 0.98 0.02
0 0.97 0.03
92 (30.2%) 0.47 0.53
2 (0.7%) 0.92 0.08
eability-increasing.
Table 3. Genotype and Allele Frequencies of the Analyzed Loci in the Donors
Wt/Wt, n (%) Wt/Variant, n (%) Variant/Variant, n (%) f(wt) f(variant)
NOD2 SNP8 272 (89.5%) 32 (10.5%) 0 0.95 0.05
NOD2 SNP12 289 (95.1%) 15 (4.9%) 0 0.98 0.02
NOD2 SNP13 278 (91.4%) 26 (8.6%) 0 0.96 0.04
BPI 70 (23.0%) 153 (50.3%) 81 (26.7%) 0.48 0.52
IL-23R 271 (89.1%) 31 (10.2%) 2 (0.7%) 0.94 0.06
f(wt or variant) indicates wt or variant allele frequency; BPI, bactericidal permeability-increasing.
1722 Biol Blood Marrow Transplant 16:1718-1727, 2010M. Wermke et al.17.4%, 95%CI, 12.5%-22.2% vsNOD2-SNP: 16.2%,
95%CI, 7.4%-25.1%; P5 .938) (Figure 1D), whereas
recipients bearing the NOD2 variant genotype tended
to have less aGVHDgrade III-IV comparedwith those
with the NOD2-wt genotype (10%; 95% CI, 2.3%-
17.7% vs 18.9%; 95% CI, 13.9%-23.9%; P 5 .104)
(Figure 1E). Again, an integrated analysis of recipient
and donor genotype found no significant differences
(Figure 1F).
BecauseNOD2 variants have been reported to cor-
relate especially closely with the risk forGIGVHD,we
also assessed this endpoint in our cohort. The cumula-
tive incidence of GI aGVHD of any grade was not
associated with donor NOD2 genotype (Figure S1A).
In contrast, there was a trend toward less GI GVHD
in recipients bearing a NOD2-SNP compared with
those with the NOD2-wt genotype (11.7%; 95% CI,Figure 1. Cumulative incidence of aGVHDwith respect to NOD2 genotype.
of the donor (A) and the recipient (B). (C) An integrated analysis according to
aGVHD according to NOD2 donor genotype (D) and recipient genotype (E)
aGVHD. In (C) and (F), recipient genotype is given before that of the donor (3.5%-19.9% vs 23.4%; 95% CI, 18.0%-28.7%; P 5
.052) (Figure S1B).
Holler et al. [2] reported a significant association of
NOD2-SNPs with GVHD when comparing patient
and donor pairs with unmutated NOD2 and those
with SNPs in the donor and/or recipient. Even under
these premises, we found no correlation of NOD2
polymorphisms with the incidence of aGVHD grade
II-IV (Figure S2A) and grade III-IV (Figure S2B).
BPI polymorphisms
Recipients of a transplant from a BPI-A donor had
a higher cumulative incidence of aGVHD grade II-IV
than recipients of a BPI-G transplant (41.8%; 95% CI,
30.1%-53.5% vs 34.6%; 95% CI, 28.5%-40.7%), but
the cumulative incidence functions did not differ signif-
icantly, as assessed byGray’s test (P5 .222) (Figure 2A).(A and B) Incidence of aGVHD grade II-IV according to NOD2 genotype
donor and recipient genotype. (D and E) Cumulative incidence of severe
. (F) An integrated analysis of donor and recipient genotype and severe
eg, ‘‘wt/SNP’’ refers to WT in the recipient and SNP in the donor).
Figure 2. Correlation of BPI genotype with the incidence of aGVHD. No significant differences in the incidence of aGVHD grade II-IV could be found
with respect to BPI donor genotype (A) and BPI recipient genotype (B). (C) An integrated analysis of aGVHD grade II-IV incidence according recipient
and donor genotype. (D and E) Cumulative incidence of aGVHD grade III-IV according to donor genotype (D) and recipient genotype (E). (F) An
integrated analysis of donor and recipient genotype and aGVHD grade III-IV. In (C) and (F), recipient genotype is given first, followed by donor genotype
(eg, ‘‘A/G’’ means A in the recipient and G in the donor).
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aGVHD incidencewith respect to patient BPI genotype
(BPI-A, 36.6%; 95% CI, 25.3%-47.9% vs BPI-G:
36.1%, 95% CI, 30.0%-42.3%; P 5 .960) (Figure 2B).
Subgroupanalysis incorporating recipient anddonorge-
notype revealed no marked differences (Figure 2C).
However, there was a trend (P 5 .068) toward less
aGVHDgrade III-IV in recipients of aBPI-G transplant
compared with recipients of a BPI-A transplant (15.0%;
95% CI, 10.4%-19.5% vs 24.6%; 95% CI, 14.4%-
34.9%). Details of the cumulative incidence functions
are shown in Figure 2D. Again, recipient BPI genotype
was not correlated with severe aGVHD (BPI-A:
18.3%; 95% CI, 9.2%-27.3% vs BPI-G: 16.8%; 95%
CI, 12.0%-21.6%; P5 .768) (Figure 2E). An integrated
analysis of recipient and donor genotypes showed that
recipients with the BPI-G genotype receiving a BPI-A
graft were the most likely of all groups to experience
aGVHD grade III-IV (Figure 2F).
When analyzed under a recessive model, no signif-
icant associations were found between aGVHD grade
II-IV and BPI donor (Figure S3A) or recipient geno-
type (Figure S3B). Similarly, analysis under these
premises revealed no association between severeaGVHD (grade III-IV) and BPI donor (Figure S3C)
or recipient genotype (Figure S3D). Assessment under
an additive geneticmodel also failed to identify a corre-
lation between BPI genotype and aGVHD (data not
shown).IL23R polymorphisms
Recipients of transplants from donors with an IL-
23R-SNP had a cumulative aGVHD incidence of
only 21.4% (95% CI, 7.1%-35.8%), compared with
38.0% (95% CI, 32.2%-43.8%) in those receiving an
IL-23R-wt graft (P5 .089) (Figure 3A). In contrast, re-
cipient IL-23R genotype was not correlated with the
occurrence of aGVHD grade II-IV, with almost equal
cumulative incidence in the two groups (wt: 36.4%;
95% CI, 30.5%-42.3% vs SNP: 35.4%; 95% CI,
21.7%-49.1%; P 5 .795) (Figure 3B).
As shown in Figure 3C, patients receiving an
IL-23R-SNP graft were less likely to develop aGVHD
regardless of recipient genotype. However, this
difference did not reach statistical significance for the
comparison of all 4 subgroups (Figure 3C). Neverthe-
less, the curves suggest that if there is any effect of
Figure 3. Cumulative incidence of aGVHD with respect to IL-23R-genotype. (A and B) IL-23R-SNP in the donor was correlated with a reduced in-
cidence of aGVHD grade II-IV (A), whereas no differences were seenwith respect to IL-23R-genotype in the recipient (B). (C) Detailed subgroup analysis
revealed a lower incidence of aGVHD grade II-IV in recipients of allo-SCT from an IL-23R-SNP donor irrespective of patient genotype. (D) The incidence
of aGVHD grade III-IV according to IL-23R donor genotype. (E) The incidence of aGVHD grade III-IV according to recipient IL-23R genotype. (F) An
integrated analysis of IL-23R donor and recipient genotype. In (C) and (F), recipient genotype is given first, followed by donor genotype.
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determinant.
The cumulative incidence of severe aGVHD (grade
III-IV) in recipients of an IL-23R-SNP graft was only
half that of recipients of an IL-23R-wt graft (9.1%;
95% CI, 0%-19.1% vs 18.1%; 95% CI, 13.5%-
22.7%). This difference did not reach statistical signif-
icance (P 5 .231), however, presumably because of the
low overall incidence of severe aGVHD (Figure 3D). In
contrast, the cumulative incidence of severe aGVHD
was not correlated with IL-23R-patient genotype (wt:
16.9%; 95% CI, 12.2%-21.5% vs SNP: 18.8%; 95%
CI, 7.6%-29.9%; P5 .591) (Figure 3E).The integrated
subgroup analysis of recipient and donor genotype
revealed no significant difference for the overall
comparison, but again the cumulative incidence of se-
vere GVHD was lowest in any scenario involving an
IL-23R-SNP graft (Figure 3F).Multivariate Analysis of Factors Influencing
GVHD Incidence
Multivariate analysis of the occurrence of aGVHD
was performed using an ordinal regression model. For
that purpose, aGVHD was grouped into 3 strata: (1)aGVHD grade 0-I, (2) aGVHD grade II, and (3)
severe aGVHD(grade III-IV).These stratawere chosen
to reflect the clinical implications of the different
aGVHD grades. Grades 0 and I typically refer to pa-
tients with clinically irrelevant or uncertain aGVHD;
most clinicians do not treat these patients systemically.
Grade II usually reflects the point at which corticoste-
roid therapy is initiated, whereas patients with aGVHD
grade III and IV have a high probability of dying from
this complication and thus are often treated more ag-
gressively. In vivo T cell depletion, donor type (related
vs unrelated), type of GVHD prophylaxis (calcineurin
inhibitor only vs calcineurin inhibitor plus other immu-
nosuppressant), sex match (female donor and male
recipient vs other), HLAmatch (10/10 match vs other),
donor IL-23R genotype (wt vs SNP), recipient NOD2
genotype (wt vs SNP), and donor BPI-A645G-SNP (A
vs G) were entered as factors potentially influencing
the incidence of aGVHD. Only in vivo T cell depletion
(hazard ratio [HR], 0.35), use of a multiagent GVHD
prophylaxis regimen (HR, 0.53), and donor IL-23R-
SNP (HR, 0.40) were identified as independent factors
correlated with a reduced risk of aGVHD. Further-
more, there was a trend toward less aGVHD in recipi-
ents of grafts from related donors (HR, 0.64) and in
Table 4. Multivariate Analysis of Factors Influencing the
Severity of aGVHD
OR 95% CI P Value
In vivo T cell depletion, yes versus no 0.32 0.17-0.60 <.001
Female donor and male recipient versus other 1.62 0.86-3.06 .133
Related donor versus unrelated donor 0.77 0.44-1.34 .351
GVHD prophylaxis multiagent versus
calcineurin inhibitor only
0.51 0.27-0.95 .033
NOD2 patient SNP versus wt 0.83 0.45-1.53 .554
IL-23R donor SNP versus wt 0.39 0.16-0.95 .039
BPI donor G allele versus A allele 0.60 0.35-1.04 .067
HLA match versus mismatch 0.57 0.32-1.21 .058
Ordinal regression modeling was used. Acute GVHD was grouped into
3 strata: (1) grade 0-I, corresponding to no or uncertain disease;
(2) grade II, marking the threshold for clinically relevant aGVHD; and
(3) severe GVHD, corresponding to grade III-IV.
Table 5. Multivariate Analysis of Factors Influencing Relapse
Incidence
OR 95% CI P Value
Disease status at transplantation,
advanced versus early
2.13 1.37-3.29 .001
In vivo T cell depletion, yes versus no 1.23 0.81-1.87 .337
NOD2 patient SNP versus wt 1.56 0.99-2.46 .056
IL-23R donor SNP versus wt 0.88 0.46-1.71 .710
BPI donor G allele versus A allele 1.44 0.85-2.44 .178
Cox regression modeling was used. Advanced disease is defined as any
disease not in complete remission or chronic phase or the presence of
MDS at time of transplantation.
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type (HR, 0.59). Recipient NOD2 genotype and sex-
mismatched transplant were not independent factors
for the occurrence of aGVHD. Details of the analysis
are presented in Table 4.
Polymorphisms and Clinical Outcome
Given the clear correlation between GVHD and
graft-versus-malignancy effects, we next investigated
whether any of the analyzed SNPs were correlated
with relapse. At 5 years, patients with an SNP at the
NOD2 locus had a cumulative relapse incidence of
46.2% (95% CI, 32.4%-60.0%), compared with
33.2% (95% CI, 26.0%-40.3%) in those recipients
with the wtNOD2 genotype, which is a statistically sig-
nificant difference (P5 .020). In contrast, there was no
difference in the 5-year cumulative incidence of relapse
between IL-23R-wt (35.1%; 95% CI, 28.3%-41.9%)
and IL-23R-SNP recipients (38.8%; 95% CI, 21.7%-
56.0%; P 5 .475). Interestingly, relapse incidence also
did not differ with respect to IL-23R donor genotype
(SNP: 34.6%; 95% CI, 17.6%-51.5% vs wt: 35.9%;
95% CI, 29.1%-42.7%; P5 .735). Furthermore, there
was no relevant difference in incidence between the
different BPI recipient genotype groups (A: 32.5%;
95% CI, 21.1%-43.9% vs G: 36.4%; 95% CI, 29.1%-
43.8%; P 5 .990) or donor genotype groups
(A: 27.3%; 95% CI, 16.4%-38.2% vs G: 37.7%; 95%
CI, 30.5%-44.9%; P 5 .396). Cox regression analysis
identified advanced disease status at allo-SCT as the
only significant independent risk factor for relapse.
NOD2-SNP in the recipient was an independent factor
of borderline significance (Table 5). The estimated
5-year OS was 34.2% in recipients with an NOD2-
SNP, compared with 44.3% in those with NOD2-wt
(P 5 .158). Survival differences based on NOD2 donor
genotype were even less remarkable, with a 5-year OS
of 42.7% in wt versus 41.6% in SNP (P 5 .300). The
same applied for recipient IL-23R genotype (5-year
OS: 42.6% inwt vs 40.6% in SNP; P5 .584) and donor
IL-23R genotype (5-year OS: 42.9% in wt vs 38.4% inSNP; P 5 .732). Recipient BPI genotype also had no
influence on OS (A, 36.5% vs G, 44.2%; P 5 .560).
Finally, BPI donor genotype was not associated with
OS (A, 44.7% vs G, 42.5%; P 5 .928).DISCUSSION
In our analysis of a cohort of 304 patients and their
related andunrelated donors,wewereunable todemon-
strate a clear effect of NOD2-SNPs on the incidence of
aGVHD. We did find a trend toward less aGVHD in
patients bearing an SNP at the NOD2 locus, but this
effect could not be confirmed in multivariate analysis.
Nevertheless, we found a higher relapse rate in this
group, with the difference almost reaching statistical
significance in multivariate analysis. In contrast, we
identified a trend toward less aGVHD in recipients of
a graft from an IL-23R(1142A.G)-SNP donor in uni-
variate analysis, and this association reached statistical
significance when assessed in a multivariate model.
Despite this, these patients did not demonstrate a higher
relapse rate. Interestingly, we saw a trend toward less
aGVHD in patients receiving a graft from a donor
with the G allele at position 645 of the BPI gene in
both the univariate and multivariate analyses; however,
this also did not result in an increased relapse rate.
Our results regarding IL-23R and BPI might be
limited by the fact that we did not adjust for multiple
comparisons. On the other hand, our intent was to
identify potential candidates for further prospective
evaluation, and thus we were reluctant to prematurely
exclude any SNP because of overly conservative signif-
icance thresholds.
Regarding NOD2-SNP8 in the recipient, we must
acknowledge that the observed genotype frequencies
were not reconcilable with the Hardy-Weinberg equi-
librium. This resulted mainly from an excess of 4 pa-
tients homozygous for this SNP. There are several
possible explanations for this surplus. Because the ex-
periments were performed with rigid quality control,
we can largely exclude genotyping errors. Another ex-
planation might be the use of a stratified study cohort
(eg, a cohort comprising 2 ormore different subpopula-
tions); however, if that were so, then we would expect
other SNPs to be in disequilibrium as well. Random
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Moreover, because 3 of these 4 patients suffered from
acute myelogenous leukemia, it also is possible that
loss of heterozygosity, a common phenomenon in
such highly genetically instable diseases, led to a loss
of the wt allele.
In general, our results are compatible with the
controversial conclusions reached by other groups
regarding NOD2-SNPs in allo-SCT. First reported
to predict the occurrence of aGVHD by Holler et al.
[2], these genetic variants were later shown to be cor-
related with relapse incidence, but not with GVHD,
in a different cohort by Mayor et al. [9]. Some other
authors failed to demonstrate any importance of
NOD2-SNPs in the posttransplantation setting, how-
ever [6,7]. It has been speculated that the effect of
NOD2-SNPs on the occurrence of GVHD is more
pronounced in matched sibling transplantations, but
diminished by the use of broad-spectrum antibiotic
prophylaxis [2]. Because antibiotic prophylaxis in our
patients was directed mainly against gram-negative
bacteria, it is unlikely that the intestinal decontamina-
tion led to the lack of correlation between aGVHD
and NOD2-SNPs. We also addressed the possibility
that the importance of NOD2 gene variants depends
on the donor type or the use of T cell-depleting
strategies by adjusting ourmultivariatemodel for these
factors, and again found no effect. This might be be-
cause we used RIC more frequently (in nearly 80%
of patients) than other groups. NOD2 might possibly
be less relevant for the occurrence of aGVHD in this
scenario, where acute organ damage is limited.
aGVHD tends to occur later after RIC, which points
to a different pathophysiological background, proba-
bly more related to CD81 T cell responses against
minor histocompatibility antigens and not directly
attributable to the acute inflammatory response seen
after intensive conditioning [20]. Despite this, we did
find an increased relapse rate in patients bearing the
NOD2 SNP. In contrast to Mayor et al. [9], we could
not relate this finding to a high proportion of cases of
acute lymphoblastic leukemia, given that only 8.2%
of our patients had acute lymphoblastic leukemia.
The functional consequences of NOD2-SNPs are
as controversial as the clinical findings. It has been
postulated that a defective NOD2 gene results in
increased peritransplantation mucosal damage, which
might be the reason for the association with GVHD
[2,8]. Interestingly, recent mouse data point to
a central role for aberrantly activated host dendritic
cells in this regard [1]. Other animal work has shown
that NOD2 is also essential for T helper cell function
[21], which would provide an explanation for increased
relapse rates in recipients of grafts from donors carry-
ing NOD2-SNPs. However, we and others [9] have
found an increased relapse rate in recipients with an
NOD2-SNP. A key problem of the aforementionedmouse models is that they use homozygous knockout
instead of the heterozygous SNPs occurring in
humans. This is underscored by data suggesting that
only double mutations (ie, the presence of 2 SNPs in
one patient) lead to a marked decrease in IL-8 produc-
tion in response to muramyl-dipeptide [22]. Thus, the
consequences of a single defective allele might be less
severe and result in phenotypic consequences only
under special circumstances. The nature of these con-
tributing factors might be elucidated in larger clinical
trials or whole genome association studies.
Our findings regarding the relevance of IL-23R-
SNP(1142A.G) corroborate data reported by Elmaa-
gacli et al. [17], who also found a lower frequency of
aGVHD in recipients of transplants from donors
with an IL-23R-SNP allele. Gruhn et al. [23] recently
reported a similar effect of this genetic variation in
a cohort of pediatric and adolescent allo-SCT
recipients. Interestingly, this study also found no effect
of NOD2 polymorphism on posttransplantation
outcome. IL-23 exerts its proinflammatory effects
through both the innate and adaptive immune systems
[24]. In the latter, IL-23 is essential for the generation
of a novel T helper cell subset, the Th17 cells, which
have been shown to induce lethal GVHD in some
mouse models [14]. Other researchers have reported
proinflammatory properties of IL-23 independent of
Th17 cells [16]. Interestingly, they found that IL-23
knockouts were selectively protected from intestinal
GVHD. Therefore, they speculated that pharmaco-
logic targeting of IL-23 might help to protect the
intestine from inflammatory damage without hamper-
ing the desired graft-versus-leukemia effect. In this
context, it is interesting that we did not find an in-
creased relapse rate in our recipients of IL-23R-SNP
transplants despite significantly less GVHD in this
group. This might be a hint that defective IL-23
signaling has similar effects in mice and humans.
Comparable to NOD2-SNPs and the IL-23R
(11421.G)-SNP, an association with inflammatory
bowel disease has also been found for BPI-SNPs
[12,25]. Moreover, BPI has been identified as
a candidate locus for the prediction of BOS after allo-
SCT [13], which points to a role of this protein in
posttransplantation immune regulation. Given BPI’s
importance in maintaining an intact mucosal barrier
and defense against commensal bacteria, altered BPI
function in the recipient can be assumed to be espe-
cially relevant. On the other hand, BPI has potent
anti-inflammatory properties, which relate to its LPS-
neutralizing function [26]. In this regard, BPI is an
antagonist to LPS-binding protein, which increases
the inflammatory response to LPS. Neutrophils are be-
lieved to be the main source of BPI in humans [27];
thus, genetic variants influencing BPI expression or
function in the donor could affect posttransplantation
immune regulation in the recipient. The functional
Biol Blood Marrow Transplant 16:1718-1727, 2010 1727SNPs and aGVHDrelevance of the studied BPI(A645G)-SNP has not yet
been formally proven, however. Furthermore, our re-
sults regarding this SNP did not reach statistical
significance, and the integrated subgroup analysis com-
bining recipient and donor genotype gave somewhat
conflicting results. Thus, it might turn out that this ge-
netic variant is merely a surrogate marker for another,
as-yet-unknownmutation, or that the association found
in our cohort is simply because of the high frequency of
BPI-G variants. Clearly, further work is needed to ad-
dress these problems, and it will be interesting to see
whether other groups reach similar conclusions.
In summary, we think that it is still too early to
incorporate NOD2-SNPs into daily practice of
donor selection or patient-specific modification of the
conditioning regimen. Cleary, results from ongoing
prospective trials are needed before final conclusions re-
garding this genetic variation can be reached. Regarding
the IL-23R(1142A.G)-SNP and BPI(A645G)-SNP,
we consider further prospective investigation war-
ranted. The IL-23R(1142A.G)SNP might be an espe-
cially promising target, possibly allowing improvement
of algorithms for donor selection.ACKNOWLEDGMENTS
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